BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, November 26, 2024
See today's BioWorld Asia
Home
» Beigene expands studies of BTK inhibitor with studies in CLL, follicular lymphoma
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Beigene expands studies of BTK inhibitor with studies in CLL, follicular lymphoma
Nov. 22, 2017
By
Pearl Liu
No Comments
HONG KONG – Beigene Ltd. is advancing its small-molecule Bruton's tyrosine kinase (BTK) inhibitor BGB-3111 into two more global clinical trials, further exploring the efficacy of the drug candidate in treating B-cell cancers.
BioWorld Asia
